Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016;16(2):137-42.
doi: 10.1517/14712598.2016.1128410. Epub 2015 Dec 23.

Totality of the evidence at work: The first U.S. biosimilar

J Holzmann  1 , S Balser  2 , J Windisch  1
Affiliations
Editorial

Totality of the evidence at work: The first U.S. biosimilar

J Holzmann et al. Expert Opin Biol Ther. 2016.

Abstract

On March 6(th) 2015, the Food and Drug Administration (FDA) approved filgrastim-sndz (Zarxio) as the first biosimilar in the United States (US) for all indications of the reference product. Filgrastim-sndz is a biosimilar of Amgen's Neupogen and is mainly used to treat neutropenia in cancer patients receiving chemotherapy. This article presents a summary of the analytical and clinical studies submitted by Sandoz and describes how the information was integrated to provide the 'totality of the evidence' leading to the approval of the biosimilar.

Keywords: Biosimilar; G-CSF; Neupogen; Zarxio; filgrastim; filgrastim-sndz; neutropenia.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources